TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Result of Annual General Meeting
Alderley Park, 9 July 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
The AGM voting results will be available on the Company's website here.
-Ends-
Enquiries
|
|||||||||
About TheraCryf plc
TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders [*orphan indication].
The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).
TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.